6-Fluoro ursodeoxycholic acid

Drug Profile

6-Fluoro ursodeoxycholic acid

Alternative Names: 6-FuDCA

Latest Information Update: 30 Apr 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Nonindustrial source; Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Primary biliary cirrhosis

Most Recent Events

  • 04 Nov 1998 New profile
  • 04 Nov 1998 Preclinical development for Cancer in USA (Unknown route)
  • 04 Nov 1998 Preclinical development for Primary biliary cirrhosis in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top